Advertisement
Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI) Stock Overview

Explore Denali Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

DNLI●NASDAQ
HealthcareBiotechnology
$20.14
$0.48(2.44%)
U.S. Market opens in 16h 8m
Advertisement

Denali Therapeutics Inc. (DNLI)

Meyka AI Score

Z

Key Financials

Market Cap3.2B
P/E Ratio-7.13
EPS (TTM)$-2.88
ROE-0.52%
Fundamental Analysis

AI Price Forecasts

1 Month$17.03
3 Months$19.70
1 Year Target$12.98

DNLI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Denali Therapeutics Inc. (DNLI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 50.13, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $12.98.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -7.13 and a market capitalization of 3.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.44%
5-Day Change
-3.41%
1-Month Change
7.87%
3-Month Change
-1.13%
6-Month Change
0.15%
Year-to-Date (YTD) Change
21.99%
1-Year Change
39.67%
3-Year Change
-33.88%
5-Year Change
-68.84%
All-Time (Max) Change
-6.11%

Contact Information

https://www.denalitherapeutics.com
650 866 8548
161 Oyster Point Boulevard, South San Francisco, CA, 94080

Company Facts

443 Employees
IPO DateDec 8, 2017
CountryUS
Actively Trading

Frequently Asked Questions